This question rarely comes up out of curiosity. It comes up when someone is stopping, switching, scheduling surgery, or planning a pregnancy. The answer starts with one number, and for tirzepatide that number is smaller than most people expect.
Quick Answer
The prescribing information for approved tirzepatide products gives an elimination half-life of about five days, which is what makes once-weekly dosing possible. Medications are generally considered cleared after roughly five half-lives, so tirzepatide is largely gone about 25 days after a final dose. That is an average from pharmacokinetic studies, not a guarantee for one person.
What a Five-Day Half-Life Means
Half-life is the time it takes for the amount of a medication in the body to fall by half. It is the single most useful number for understanding how a medication behaves, and it explains three things patients notice.
Why the injection is weekly. A medication that halves over five days can be given once a week and still hold a workable level. The schedule follows from the chemistry rather than from convenience.
Why week two feels different from week eight. With any repeatedly dosed medication, levels climb until the amount leaving each week matches the amount going in. That plateau, called steady state, is why the same dose can feel different early and later.
Why a missed dose does not reset anything. After a skipped week, a substantial share of the previous dose is still present. What to do about a missed dose is a question for the prescriber rather than for arithmetic, but the medication has not disappeared.
Clearance After a Final Dose
| Time since last dose | Roughly how much remains |
|---|---|
| 5 days | about half |
| 10 days | about a quarter |
| 15 days | about an eighth |
| 20 days | about a sixteenth |
| 25 days | generally considered cleared |
This is the standard five-half-lives arithmetic applied to the labeled half-life, and it is an approximation for a typical adult. Real elimination varies with kidney and liver function, the dose reached, how long treatment continued, and individual metabolism. Anyone who needs a precise answer for a medical reason should get it from their own clinician, who can account for those factors.
Tirzepatide Versus Semaglutide
This is the comparison people actually want, and it is a fair one to make because both figures come from the same kind of source: the prescribing information for the approved products.
| Labeled half-life | Roughly cleared after | |
|---|---|---|
| Tirzepatide | about 5 days | about 25 days |
| Semaglutide | about 1 week | about 5 weeks |
The semaglutide labeling goes further and states directly that the medication will be present in circulation for about five weeks after the last dose. Tirzepatide clears the faster of the two, by roughly a fortnight.
That difference matters in three practical places: a shorter washout when a prescriber plans a switch, a shorter tail of side effects after stopping, and a different conversation before a procedure. It is not a reason to prefer one medication over the other. Which one suits a person depends on their history, and that is the physician's call. Our companion piece covers how long semaglutide stays in your system.
Compounded medications are not FDA-approved as final products and have not been evaluated by the FDA for safety, effectiveness, or quality. The half-life figures above come from the labeling of the approved products and describe the molecule.
The Three Situations Behind This Question
Stopping treatment
Levels fall over weeks, so most people describe appetite returning gradually rather than overnight. Digestive effects follow their own timeline, and tirzepatide constipation covers the one that most often outlasts the first month. Weight regain after stopping GLP-1 treatment is common and well documented, which is a separate subject we cover in keeping weight off after GLP-1. If you are considering stopping, the conversation to have is with the prescriber, before rather than after.
Surgery or a procedure
Tell the surgical and anaesthesia teams that you take a GLP-1 medication, and tell them early rather than on the morning. These medications slow stomach emptying, which is the reason anaesthesia teams ask. Whether to pause, and for how long, is set by those teams together with your prescriber. It is not a calculation to do at home, and this article deliberately gives no interval.
Planning a pregnancy
The labeling for approved GLP-1 products addresses use in pregnancy, and the timing of stopping before trying to conceive is a decision for the prescriber and, where relevant, an obstetric clinician. Bring the date of your last dose: it is the piece of information they need and the one only you have.
What This Number Is Not
It is not a schedule for restarting, a licence to change a dose, or a way to time a switch without telling anyone. It is one input a clinician uses among several. The useful thing you can do with it is arrive at the conversation knowing your last dose date and roughly where you sit on the curve.
Frequently Asked Questions
How long does tirzepatide stay in your system?
The prescribing information for approved tirzepatide products gives an elimination half-life of approximately five days. Medications are generally considered cleared after roughly five half-lives, which puts full clearance at about 25 days, so a little under a month after a final dose. That is an average drawn from pharmacokinetic studies rather than a promise about any individual: kidney and liver function, the dose reached, and how long someone has been treated all shift the real figure.
What is the half-life of tirzepatide?
About five days, according to the prescribing information for approved tirzepatide products, which describes that half-life as what enables once-weekly dosing. Half-life is the time it takes for the amount of a medication in the body to fall by half. It also explains why levels keep climbing for the first weeks of treatment before leveling off, and why a single missed dose does not empty the system.
Does tirzepatide leave the body faster than semaglutide?
Yes, and by a meaningful margin. Approved tirzepatide products are labeled with a half-life of about five days; approved semaglutide products are labeled with a half-life of about one week, and the semaglutide labeling states the medication will be present in circulation for about five weeks after the last dose. Roughly a month against roughly five weeks. Neither number is a reason to change anything on your own: what to do about stopping, pausing or switching is a decision for the prescriber.
I have surgery coming up. What should I do?
Tell the surgical team and the anaesthesia team that you take a GLP-1 medication, and tell them as early as you can rather than on the day. GLP-1 medications slow stomach emptying, which is why anaesthesia teams want to know in advance. The interval, if any, is theirs to set together with your prescriber, and it is not something to work out from a half-life at home.
How long do side effects last after stopping?
Because levels fall gradually rather than at once, people generally describe effects easing over weeks rather than overnight. If a side effect is severe, is getting worse, or has not settled well after stopping, that is a reason to contact your clinician rather than to wait out the arithmetic.
Can I switch from tirzepatide to another GLP-1 straight away?
That is a clinical decision, and the overlap between one medication clearing and another starting is exactly the part a prescriber has to plan. Bring the date of your last dose to the conversation, because that is the piece of information they need and the piece only you have.
Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date.
- US-licensed physicians affiliated with our clinical partner MD Integrations
- Practicing in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across states planned for launch through the MD Integrations Medical Services Organization (coverage varies by state and clinician licensure; see our states page)
- Dispensing pharmacy partner: Belmar Pharma Solutions; Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy